Revvity, Inc.

Revvity, Inc. is an American health sciences company headquartered in Waltham, Massachusetts, that provides instruments, reagents, software, and services spanning drug discovery through clinical diagnostics, generating $2.86 billion in revenue in fiscal 2025. Formerly known as PerkinElmer, the company completed a foundational transformation in 2023 by divesting its legacy analytical instruments, food, and environmental testing businesses for approximately $2.3 billion, rebranding, and refocusing entirely on two segments — Life Sciences and Diagnostics — that serve pharmaceutical, biotech, academic, and clinical laboratory customers in more than 160 countries.

The investment question at the heart of this file is whether the slimmed-down Revvity can deliver durable mid-single-digit revenue growth and margin expansion after absorbing a punishing post-COVID revenue decline, persistent tariff headwinds, and a cautious government-funded research spending environment. The stock trades at roughly 48 times trailing earnings from continuing operations, a premium that prices in a return to growth that the income statement has not yet clearly delivered.